Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Bauml, Joshua
Seiwert, Tanguy Y.
Pfister, David G.
Worden, Francis P.
Liu, Stephen V.
Gilbert, Jill
Saba, Nabil F.
Weiss, Jared
Wirth, Lori J.
Sukari, Ammar
Kang, Hyunseok
Gibson, Michael K.
Massarelli, Erminia
Powell, Steven Francis
Meister, Amy
Shu, Xinxin
Cheng, Jonathan D.
Haddad, Robert I.
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Georgetown Univ Hosp, Washington, DC 20007 USA
[6] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Univ Hosp Case Med Ctr, Cleveland, OH USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Sanford Hlth, Sioux Falls, SD USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6011
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
    Haddad, R.
    Seiwert, T.
    Pfister, D. G.
    Worden, F.
    Liu, S. V.
    Gilbert, J.
    Saba, N. F.
    Weiss, J.
    Wirth, L. J.
    Sukari, A.
    Kang, H.
    Gibson, M. K.
    Massarelli, E.
    Powell, S.
    Meister, A.
    Shu, X.
    Cheng, J.
    Bauml, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.
    Powell, Steven Francis
    Liu, Stephen V.
    Sukari, Ammar
    Chung, Christine H.
    Bauml, Joshua
    Haddad, Robert I.
    Gause, Christine K.
    Niewood, Michelle
    Gammage, Linda L.
    Brown, Holly
    Meister, Amy
    Cheng, Jonathan D.
    Gitau, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Biomarkers of resistance to cetuximab in head and neck squamous cell carcinoma (HNSCC).
    Surikova, Ekaterina I.
    Kit, Oleg I.
    Neskubina, Irina V.
    Frantsiyants, Elena M.
    Vladimirova, Liubov Yu
    Lyanova, Aza A.
    Engibaryan, Marina A.
    Shalashnaya, Elena V.
    Aedinova, Irina V.
    Ulianova, Yulia V.
    Volkova, Viktoriya L.
    Pustovaya, Irina Viktorovna
    Ezhova, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] PTEN and cetuximab resistance in head and neck squamous cell carcinoma (HNSCC).
    Da Costa, Alexandre Andre B. A.
    Costa, Felipe D'Almeida
    De Oliveira, Andrea Cruz Ferraz
    Stecca, Carlos
    Oliveira, Audrey
    Alves, Ana Caroline Fonseca
    Camandaroba, Marcos Pedro Guedes
    Araujo, Daniel Vilarim
    Machado, Larissa
    De Lima, Vladmir Claudio Cordeiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Patterns of Failure after IMRT in Head and Neck Squamous Cell Carcinoma (HNSCC)
    Spencer, C. R.
    Gay, H.
    Deasy, J. O.
    El Naqa, I.
    Haughey, B. H.
    Adkins, D.
    Thorstad, W. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S427 - S428
  • [6] Pembrolizumab plus chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
    Tahara, Makoto
    Machiels, Jean-Pascal
    Tao, Yungan
    Burtness, Barbara
    Rischin, Danny
    Alves, Gustavo V.
    Lima, Iane Pinto Figueiredo
    Hughes, Brett G. M.
    Pointreau, Yoann
    Aksoy, Sercan
    Laban, Simon
    Greil, Richard
    Burian, Martin
    Hetnal, Marcin
    Licitra, Lisa
    Swaby, Ramona
    Zhang, Yayan
    Bidadi, Behzad
    Siu, Lillian L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [7] Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
    Haddad, Robert I.
    Seiwert, Tanguy Y.
    Chow, Laura Quan Man
    Gupta, Shilpa
    Weiss, Jared
    Gluck, Iris
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Kang, Hyunseok
    Muro, Kei
    Albright, Andrew
    Huang, Lingkang
    Ayers, Mark
    Mogg, Robin
    Cristescu, Razvan
    Cheng, Jonathan D.
    Mehra, Ranee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma
    Yao, Zhuowei
    Wang, Jingshuo
    Jiang, Yongquan
    Zhang, Yi
    Liu, Jun
    Dai, Li
    Shen, Silin
    Zhou, Xiang
    Liu, Qiang
    Zheng, Luying
    Qian, Minfei
    Li, Jiping
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025, 47 (01): : 289 - 299
  • [9] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios
    ORAL ONCOLOGY, 2024, 158
  • [10] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
12345